No Data
On December 30th, A-share investment shields︱Kangxi Communication: Shareholder Yancheng Semiconductors and Gongqingcheng Kangsheng plan to reduce their Shareholding by no more than 3%.
Shareholders of Zhejiang Shengda Bio-Pharm, Wanjian Investment, plan to reduce their shareholding by no more than 3%; multiple shareholders of Montage Technology plan to collectively reduce their shareholding by no more than 2%; South Chip Technology has cumulatively reduced its shareholding by 1% in Shanghai; shareholders of Kangxi Communication, Yancheng Semiconductors and Gongqingcheng Kangsheng, plan to reduce their shareholding by no more than 3%; Jiangsu Zhongshe Group has terminated its plan for a significant asset restructuring; First Tractor has terminated its significant asset sale; Kexing Biopharm has terminated the clinical trial of its interferon α2b spray.
Zhejiang Shengda Bio-Pharm (603079.SH): Wanjian Investment plans to shareholding no more than 3% of its shares.
Gelonghui reported on December 27 that Zhejiang Shengda Bio-Pharm (603079.SH) announced that Wanjian Investment plans to reduce its shareholding in the company by no more than 5,135,668 shares within three months after 15 trading days from the announcement of this shareholding reduction plan, with a reduction ratio not exceeding 3% of the company's total share capital.
Zhejiang Shengda Bio-Pharm (603079.SH) has successfully passed the Shanghai Stock Exchange's review for the issuance of stocks to specific individuals.
Zhejiang Shengda Bio-Pharm (603079.SH) announced that the company recently received a notice from the Shanghai Stock Exchange listing review center "...
zhejiang shengda bio-pharm (603079.SH): folic acid raw materials are all purchased externally
Grain alliance November 22nd, zhejiang shengda bio-pharm (603079.SH) stated on the investor interaction platform that folic acid is one of our main products, and the raw materials of folic acid are all purchased externally.
Guosheng Securities: Sufficient folic acid inventory has been cleared, and the turning point has appeared. The industry structure continues to be concentrated.
Benefiting from the growth of high-value-added human demand, the global demand for folic acid reached 2,100 tons in 2023, of which domestic demand increased from 310 tons in 2019 to 600 tons, with a compound growth rate of 17.95%.
Subdued Growth No Barrier To Zhejiang Shengda Bio-Pharm Co., Ltd. (SHSE:603079) With Shares Advancing 28%
Zhejiang Shengda Bio-Pharm Co., Ltd.'s (SHSE:603079) Shares Bounce 26% But Its Business Still Trails The Industry
